Five APAC Markets, Five Regulatory Models: What Developers Should Know
By Eddie H.P. Tan, Duke-NUS Medical School Center of Regulatory Excellence, on behalf of the ISCT APAC Industry Committee Regulatory Roadmap Workgroup

For cell and gene therapy (CGT) developers, Asia-Pacific (APAC) is gaining traction as a destination of choice. It is a strategically important development, manufacturing, clinical research, and commercial region. Yet APAC does not consist of one market, one regulator, or one pathway.
The ISCT APAC Industry Committee’s two regulatory-roadmap papers examine five leading jurisdictions, first on Japan, South Korea, and Singapore in 2025, and more recently on Taiwan and China. Together, we noted that regional opportunity is substantial, but success depends on treating regulatory strategy as an early product-development function rather than a late-stage filing exercise. The two papers provide high-level regulatory guidance across five dynamic, but materially and uniquely different, CGT markets.
APAC’s clinical-development footprint is expanding rapidly. In 2025, the region surpassed North America in active CGT clinical trials, with China contributing substantially to this growth. This evolution makes it increasingly important for companies outside the region, as well as APAC-based developers, to consider how local product classification, pathway selection, clinical evidence, manufacturing, data governance, and access requirements affect the wider global development plan.
Our Key Findings
1. APAC is a portfolio of markets
The five jurisdictions share a common policy objective to promote innovation and enable patient access while retaining safeguards appropriate for products with complex manufacturing, long-term safety, and efficacy uncertainties.
However, each jurisdiction has approached that objective differently:
- Japan operates a dual system comprising the Pharmaceuticals and Medical Devices Act (PMD Act) for commercial regenerative medical products and the Act on the Safety of Regenerative Medicine (ASRM) for regulated clinical practice and research.
- Singapore applies a risk-based framework for Cell, Tissue and Gene Therapy Products (CTGTPs), distinguishing lower-risk Class 1 products from higher-risk Class 2 products.
- South Korea separates Advanced Regenerative Medicine (ARM) from Advanced Biopharmaceutical Products (ABP), with distinct medical-practice and commercial-product routes.
- China combines a National Medical Products Administration (NMPA)-regulated drug-development track with a National Health Commission-linked technology track for qualifying clinical research and translational use of new biomedical technologies.
- Taiwan has formalized a comparable dual-track system under its Regenerative Medicine Act and Regenerative Medicinal Products Act: one route regulates regenerative medicine practice, while the other supports pharmaceutical-style development and product registration.
The intention of the roadmap project was not to compare if one jurisdiction is inherently “faster” than another. Our analysis informs us that a product’s classification, intended use, evidence package, manufacturing model, and commercialization plan determine which pathway is relevant, and whether that pathway supports the company’s longer-term objectives.
2. Conditional approval is not a shortcut
A central theme that we noted across the five jurisdictions is the increasing use of conditional, accelerated, or expedited mechanisms for qualifying products, particularly those targeting serious or life-threatening conditions, rare diseases, or areas where there is a substantial unmet medical need. These approaches align with the recognition that CGTs may be difficult to study in large, conventional confirmatory trials before patients could potentially benefit from access.
- Japan’s conditional and time-limited approval scheme allows regenerative medical products to receive conditional authorization where exploratory clinical data support presumed efficacy, subject to post-marketing surveillance and confirmation of efficacy within a defined period of up to seven years. Japan’s SAKIGAKE designation can also provide prioritized consultation, rolling submission, and expedited review for innovative products intended to address serious unmet needs.
- South Korea permits conditional approval of qualifying advanced biopharmaceuticals for serious or rare diseases, with confirmatory Phase 3 evidence expected after marketing authorization.
- Singapore’s framework allows conditional approval for CTGTPs addressing unmet medical needs, subject to necessary follow-up on safety and efficacy.
- China provides several accelerated routes — including Breakthrough Therapy designation, Conditional Approval, Priority Review, and Special Review and Approval
- Taiwan’s regenerative medicinal product framework includes conditional approval and expedited or abbreviated review mechanisms.
For developers, the strategic insight is clear in that conditional approval does not reduce developmental requirements but rather shifts focus to the importance of development process sequencing. The evidence burden moves across the product lifecycle rather than disappearing altogether. This calls for a credible approach that can anticipate confirmatory studies, long-term follow-up, pharmacovigilance, risk management, manufacturing consistency, and post-market commitments before the first application is submitted.
3. Dual pathways expand access
A second distinguishing feature across these markets is the presence of regulated routes outside conventional commercial marketing authorization.
- Japan’s ASRM permits medical institutions to provide certain regenerative medicine interventions within a risk-based, committee-reviewed framework that is distinct from PMD Act product authorization.
- South Korea’s ARM pathway provides a regulated framework for clinical research and, for eligible patients with serious, life-threatening, rare, or incurable diseases, ARM therapy.
- Singapore enables Special Access Routes for unregistered Class 2 CTGTPs on a named-patient basis and recognizes tightly governed innovative salvage therapy in appropriate healthcare settings.
- China’s evolving framework distinguishes the NMPA-led drug track for industry-sponsored development and commercialization from a technology track for eligible hospital-led clinical research and translational application of new biomedical technologies.
- Taiwan’s regulated regenerative medicine practice route enables approved institutions to provide specified autologous cell therapies under defined conditions, while a parallel Taiwan Food and Drug Administration (TFDA) product-registration pathway remains available for standardized, commercial regenerative medicinal products.
These alternative pathways should not be misunderstood as substitutes for commercial authorization. Their purpose, oversight structures, permissible claims, setting of use, charging arrangements, evidence requirements, and ability to support wider product commercialization differ substantially. The key question for a sponsor is not simply, “Can the product reach patients earlier?” but rather, “Which regulated route is compatible with our scientific, operational, commercial, and evidence-generation strategy?”
4. Classification drives strategy
Before considering review timelines or launch sequencing, developers need to establish how a product will be classified in each intended market. Cell source, degree of manipulation, homologous or nonhomologous use, genetic modification, manufacturing process, intended indication, and whether the product is combined with a device can all influence the applicable framework.
- For example, Singapore’s CTGTP framework distinguishes Class 1 from Class 2 products using risk-based criteria. Japan, South Korea, Taiwan, and China likewise differentiate products according to characteristics that shape regulatory expectations. A product classified as a commercial advanced biopharmaceutical or regenerative medicinal product will face a different evidence and CMC (chemistry, manufacturing, and controls) pathway from a product or practice evaluated under a regulated institutional access mechanism.
This is why classification should be discussed alongside target product profile development, not after the core CMC, nonclinical, and clinical packages have been designed. An early jurisdictional classification assessment can prevent later redesign of development plans, comparability packages, clinical protocols, manufacturing controls, or commercial supply arrangements.
Manufacturing Is A Regulatory Issue
CGT regulation is often discussed through the lens of clinical authorization and market approval. But across all five jurisdictions, manufacturing is inseparable from the regulatory strategy.
The roadmaps consistently emphasize the importance of quality systems, product characterization, donor eligibility where applicable, potency approaches, process validation, traceability, chain of identity, chain of custody, and long-term safety monitoring. For globally developed products, the location of manufacturing, local testing expectations, importation arrangements, and technology-transfer feasibility may materially affect whether a development program can meet jurisdiction-specific requirements.
This is particularly relevant for autologous therapies, personalized products, gene-edited products, and products using complex or evolving manufacturing platforms. Developers should avoid treating manufacturing localization, testing, and supply-chain design as matters to resolve only after clinical proof of concept. In APAC, as elsewhere, CMC readiness is central to development speed and commercial credibility.
Harmonization Can Begin With Clarity
There is no single APAC regulator, and it would be neither realistic nor necessarily desirable to expect all jurisdictions to adopt identical legislation. Each country has its own healthcare system, legal framework, innovation priorities, patient-access needs, and risk-management approach.
However, the five jurisdictional roadmaps reveal productive opportunities for greater practical alignment. These include common terminology; more consistent treatment of product classification concepts; shared principles for CMC, comparability, and long-term follow-up; interoperable approaches to evidence generation; and greater exchange of regulatory-science experience. Singapore’s participation in the ACCESS Consortium, a coalition of regulatory authorities in Australia, Canada, Switzerland, and the UK, to speed up access to safe and effective medicine, and its advanced therapy medicinal products (ATMP) working group illustrates how regulatory collaboration can support scientific discussion and potential convergence without eliminating national decision-making.
For companies, regulatory harmonization should be viewed not only as a public-policy ambition but also as a development-planning opportunity. A well-structured global evidence package that recognizes areas of commonality, while identifying genuinely local requirements early, can reduce duplication and make multi-jurisdictional development more efficient.
What Developers Should Do First
The regulatory roadmap project was not meant to replace product-specific regulatory advice but to improve the questions asked early enough to shape decisions.
Before selecting a first APAC market, establishing manufacturing, or initiating a pivotal program, CGT developers should ask themselves the following questions:
- Product classification: How will the product be categorized in each jurisdiction, and does this alter the applicable pathway?
- Pathway selection: Is the objective conventional product registration, conditional or expedited approval, regulated clinical access, or a staged combination of these?
- Evidence strategy: Can global data be leveraged, and where may local evidence, bridging work, or jurisdiction-specific follow-up be needed?
- Manufacturing readiness: Can the CMC package, product testing, logistics, traceability systems, and supply model meet local expectations?
- Local implementation: Are local sponsors, marketing authorization holders, clinical partners, manufacturers, or data-governance arrangements required or strategically advantageous?
- Lifecycle planning: What confirmatory studies, risk-management activities, and post-market obligations will apply if an accelerated or conditional route is pursued?
- Commercial viability: How do the intended pathway and evidence plan support reimbursement, pricing, scale-up, and sustainable market access?
Having answers to these questions will not completely remove the challenges inherent in developing advanced therapies but can help developers substantially reduce avoidable delay and prevent a technically viable program from becoming misaligned with the pathway needed to reach patients.
Building A More Navigable Region
The ISCT APAC Industry Committee created the regulatory-roadmap series to offer product developers, sponsors, researchers, and investors a practical starting point for navigating these jurisdiction-specific frameworks. The goal is not to suggest that development across APAC is simple. It is to make complexity visible, structured, and manageable.
Japan, South Korea, Singapore, Taiwan, and China each offer meaningful opportunities for CGT development and patient access. Their differences should be treated as lessons for strategic design inputs. For a field defined by scientific complexity and urgent patient need, earlier regulatory clarity can enable better planning, lower avoidable risk, accelerate appropriate access, and support more durable commercial outcomes across the region.
References:
- Tan, E. H. P., Chinchalongporn, V., Dumadi, F., Tsurumaki, Y., Jung, M. H., Kellathur, S. N., Kitawaki, Y., Ishiwatari, A., Okada, M., Oumi, Y., Nonaka, M., Lee, A., Macpherson, J. L., Velickovic, Z., & Milligan, W. (2025). Pursuing cell therapy approvals in APAC: Your guide to navigating regulations in Japan, South Korea, and Singapore. Cytotherapy, 27(9), 1043–1059. https://doi.org/10.1016/j.jcyt.2025.03.504
- Chinchalongporn, V., Dumadi, F., Liao, W.-C., Ang, W. X., Macpherson, J. L., Velickovic, Z., Milligan, W., & Tan, E. H. P. (2026). Pursuing Cell Therapy Approvals in APAC: Your Guide to Navigating Regulations in China and Taiwan. Cytotherapy, 103009. https://doi.org/10.1016/j.jcyt.2026.103009
About The Author:
Eddie H.P. Tan is an assistant professor at the Centre of Regulatory Excellence at Duke-NUS Medical School, National University of Singapore (NUS). He currently co-leads a collaborative project with the Ministry of Health and the Health Sciences Authority in Singapore to study regulatory innovation of emerging healthcare technologies. He has more than 10 years of experience in the development of cell and gene therapies, most recently as scientific officer of the National Cell and Gene Therapy Facility in Singapore. He is experienced in process and analytical development, validation and qualification, and quality management systems for cell and gene therapy clinical manufacturing.